CDC42 and cancer: The crosstalk between the Cdc42 molecule and the network of effectors in the immune system is increasingly recognized, and new therapeutic targets based on new regulator partners are expected, and their translation into the treatment strategies for cancer creating a future therapeutic perspective (El Masri and Delon, 2021).